What Should Life Sciences Organizations Expect From their PV Partner

Introduction 

Pharmacovigilance (PV) has evolved from a primarily operational reporting function into a strategic component of the life sciences ecosystem. As regulatory expectations become increasingly complex and products are marketed across multiple countries, life sciences organizations need more than a service provider that simply processes Individual Case Safety Reports (ICSRs). They need a reliable pharmacovigilance partner capable of supporting compliance, protecting patients, managing emerging risks, and providing meaningful oversight throughout the product lifecycle. 

Selecting the right PV partner is therefore a strategic decision. The relationship should extend beyond service delivery and focus on quality, regulatory compliance, scientific expertise, transparency, responsiveness, technology, and continuous improvement. 

A strong PV partner should function as an extension of the organization’s own pharmacovigilance system—bringing the expertise, processes, infrastructure, and oversight needed to maintain an effective and inspection-ready PV operation. 

1. Regulatory Expertise Across Markets 

One of the first expectations from a PV partner should be a strong understanding of the regulatory landscape in the countries where the organization operates. 

Global requirements are not identical. While international standards such as Good Pharmacovigilance Practices (GVP) and ICH guidelines provide important foundations, local authorities may impose additional requirements concerning: 

• Local PV contacts or QPPV/LQPPV arrangements. 
• Safety reporting timelines. 
• Local regulatory submissions. 
• Risk management requirements. 
• Periodic safety reports. 
• Pharmacovigilance system documentation. 
• Language and translation requirements. 
• Local safety databases or reporting platforms. 
• Regulatory inspections. 

A capable PV partner should therefore combine global PV knowledge with local regulatory expertise. 

The partner should proactively monitor regulatory changes and assess their potential impact rather than waiting for the client to identify new requirements. 

2. A Clearly Defined Pharmacovigilance Operating Model

Before activities begin, responsibilities between the life sciences organization and its PV partner should be clearly established. 

A robust operating model should define: 

• Which activities are outsourced. 

• Which activities remain with the MAH. 

• Roles and responsibilities of each party. 

• Escalation pathways. 

• Safety data exchange requirements. 

• Reporting timelines. 

• Regulatory responsibilities. 

• Quality responsibilities. 

• Business continuity arrangements. 

• Governance and communication mechanisms. 

These responsibilities should be documented through appropriate agreements, such as a Safety Data Exchange Agreement (SDEA) or other contractual arrangements applicable to the scope of services. 

The objective is to eliminate ambiguity. When a safety issue arises, everyone should know who is responsible, who needs to be informed, and how quickly action must be taken.

3. Reliable ICSR Management

Individual Case Safety Report processing remains a fundamental component of pharmacovigilance. 

A PV partner should have robust processes for: 

1. Receipt of safety information. 
2. Case identification and triage. 
3. Data entry and case creation. 
4. Medical assessment. 
5. Seriousness and expectedness assessment. 
6. Causality assessment where applicable. 
7. Coding. 
8. Quality review. 
9. Follow-up. 
10. Regulatory submission. 
11. Case reconciliation and closure. 

However, quality should not be measured solely by the number of cases processed. 

A strong PV partner should focus on accuracy, consistency, timeliness, and clinical quality while maintaining appropriate documentation and audit trails. 

The partner should also have effective mechanisms for identifying duplicate cases and obtaining meaningful follow-up information when required. 

4. Signal Detection and Safety Surveillance

A modern PV partner should not simply process incoming cases—it should help organizations understand what the accumulated safety data means. 

Signal management should include appropriate: 

• Signal detection methodologies. 

• Data review. 

• Signal validation. 

• Signal prioritization. 

• Medical assessment. 

• Documentation. 

• Escalation. 

• Regulatory impact assessment. 

• Ongoing monitoring. 

Signals can arise from spontaneous reports, literature, clinical studies, epidemiological evidence, regulatory communications, and other safety sources. 

The PV partner should have the expertise to distinguish between a statistical observation and a clinically meaningful safety concern. 

Most importantly, the partner should communicate what the data may mean for the product’s benefit–risk profile, not simply provide a list of numerical findings. 

5. Strong Medical and Scientific Expertise

Pharmacovigilance decisions require scientific judgment. 

A life sciences organization should expect its PV partner to have access to appropriately qualified professionals capable of evaluating: 

• Clinical relevance. 

• Biological plausibility. 

• Temporal relationships. 

• Alternative explanations. 

• Known and emerging risks. 

• Special populations. 

• Benefit–risk considerations. 

• Medical literature. 

• Safety signals. 

Scientific expertise becomes particularly important when dealing with complex cases, serious adverse events, emerging signals, product-specific risks, or regulatory inquiries. 

The partner should be able to explain the reasoning behind a PV conclusion, not merely provide an operational output.

6. Proactive Regulatory Compliance

A valuable PV partner should be proactive rather than reactive. 

This means identifying potential compliance risks before they become regulatory findings. 

Examples include monitoring: 

• Reporting timelines. 

• Submission compliance. 

• Training completion. 

• Reconciliation activities. 

• Literature surveillance. 

• Signal review timelines. 

• Periodic reporting deadlines. 

• Regulatory commitments. 

• CAPA actions. 

• Vendor performance. 

• Agreement implementation. 

Compliance dashboards and Key Performance Indicators (KPIs) should provide the client with visibility of performance and emerging risks. 

The goal should be continuous compliance, rather than compliance only when an audit or inspection is approaching.

7. Inspection Readiness

Every life sciences organization should expect its PV partner to contribute to inspection readiness. 

A strong partner should be able to demonstrate that its processes are: 

• Documented. 

• Implemented. 

• Controlled. 

• Monitored. 

• Auditable. 

• Supported by appropriate training. 

• Consistent with applicable regulations. 

The partner should maintain appropriate records and be able to provide evidence supporting PV activities when requested. 

Inspection readiness also requires preparation for difficult questions, such as: 

How do you know your process is effective? 

How do you ensure outsourced activities are controlled? 

How do you monitor compliance? 

How are safety signals escalated? 

What happens when a reporting deadline is missed? 

A mature PV partner should already have documented answers to these questions through its quality system and operational controls. 

8. Quality Management and Continuous Improvement

Quality should be embedded in the PV partner’s operating model. 

A comprehensive PV Quality Management System should address areas such as: 

• SOP management. 

• Training. 

• Deviations. 

• CAPA. 

• Change control. 

• Audits. 

• Quality checks. 

• Vendor management. 

• Business continuity. 

• Document control. 

• Periodic quality review. 

Importantly, quality should not be viewed simply as identifying errors. 

A strong partner should analyze trends, identify recurring issues, investigate root causes, and implement sustainable corrective actions. 

This creates a culture of continuous improvement rather than repetitive issue correction.

9. Transparent Communication and Escalation

Effective communication is one of the most important characteristics of a successful PV partnership. 

The client should have clear visibility regarding: 

• Current workload. 

• Compliance status. 

• Emerging safety concerns. 

• Regulatory requests. 

• Deviations. 

• CAPAs. 

• Critical issues. 

• Submission status. 

• Upcoming deadlines. 

More importantly, the partner should know when to escalate. 

A safety or compliance concern should never remain hidden within an operational workflow simply because it has not yet reached a formal reporting threshold. 

A good escalation framework should define the issue severity, responsible stakeholders, escalation timelines, and communication channels. 

10. Technology and Data Security

Technology plays an increasingly important role in modern pharmacovigilance. 

A capable PV partner should use appropriate systems to support: 

• Safety case processing. 

• Workflow management. 

• Medical review. 

• Signal detection. 

• Regulatory reporting. 

• Document management. 

• Reconciliation. 

• Metrics and dashboards. 

• Audit trails. 

Technology should improve quality and efficiency without replacing appropriate human medical and scientific judgment. 

Data security is equally important. Pharmacovigilance systems may contain sensitive patient information and confidential product data. The PV partner should therefore maintain appropriate controls for data protection, access management, cybersecurity, backup, and business continuity in accordance with applicable requirements. 

11. Effective Vendor and Subcontractor Oversight

PV partners may themselves rely on subcontractors or specialized service providers. 

This creates an additional layer of responsibility. 

The primary PV partner should maintain appropriate oversight of subcontracted activities, including: 

• Qualification. 

• Contractual controls. 

• Defined responsibilities. 

• Training. 

• Performance monitoring. 

• Quality monitoring. 

• Audits where appropriate. 

• Escalation. 

• CAPA management. 

The life sciences organization should understand who is actually performing each activity within the PV supply chain. 

Outsourcing should never result in a loss of accountability or visibility. 

12. Business Continuity and Resilience

Pharmacovigilance activities must continue even when unexpected disruptions occur. 

A reliable PV partner should have documented business continuity and disaster recovery arrangements covering scenarios such as: 

• System failures. 

• Cybersecurity incidents. 

• Loss of key personnel. 

• Office disruption. 

• Major technology outages. 

• Regulatory emergencies. 

• Unexpected increases in case volumes. 

Business continuity planning should be tested periodically rather than existing only as a written document. 

The organization should have confidence that critical PV activities—including safety reporting and regulatory communication—can continue during a disruption. 

13. Scalability as the Business Grows

Life sciences organizations rarely remain static. 

A company may launch new products, enter new markets, acquire another company, expand its portfolio, or experience significant changes in safety-reporting volumes. 

The PV partner should therefore be able to scale its services without compromising quality. 

This may include supporting: 

• New product onboarding. 

• New country launches. 

• Increased case volumes. 

• Additional regulatory requirements. 

• New safety databases. 

• Changes in organizational structure. 

• Mergers and acquisitions. 

• New therapeutic areas. 

Scalability should be considered during partner selection—not only when growth occurs. 

14. Governance and Performance Management

A successful PV partnership requires structured governance. 

Regular governance meetings should provide an opportunity to review: 

• KPIs and Quality KPIs. 

• Compliance performance. 

• Case volumes. 

• Reporting timeliness. 

• Signal activities. 

• Regulatory developments. 

• Deviations and CAPAs. 

• Audit findings. 

• Training. 

• Upcoming activities. 

• Improvement opportunities. 

The purpose of governance should not be limited to reviewing historical performance. 

It should also answer: 

What risks are emerging? 

What needs attention now? 

What can be improved before it becomes a problem? 

This transforms governance from a reporting exercise into a strategic management tool. 

15. Strategic Partnership Rather Than Transactional Outsourcing

Perhaps the most important expectation is that a PV partner should operate as a strategic extension of the organization’s PV function. 

A transactional provider asks: 

“What task should we perform?” 

A strategic PV partner asks: 

“What does this information mean, what risk does it create, and what should we do next?” 

This difference can significantly influence the quality of the overall pharmacovigilance system. 

The best partnerships are built on trust, transparency, scientific expertise, accountability, and shared commitment to patient safety. 

16. Questions to Ask When Selecting a PV Partner

Before entering into a partnership, life sciences organizations should consider asking: 

Regulatory Capability 

• Does the partner understand the regulations in our target markets? 

• How do they monitor regulatory changes? 

• Can they support local PV requirements? 

Operational Capability 

• What is their ICSR processing model? 

• How do they manage workload fluctuations? 

• What are their quality controls? 

Scientific Capability 

• Who performs medical review? 

• How are signals detected and assessed? 

• What expertise is available for complex safety issues? 

Quality 

• How are deviations and CAPAs managed? 

• How is vendor performance monitored? 

• How is inspection readiness maintained? 

Technology 

• Which safety systems are used? 

• How are data integrity and security maintained? 

• What reporting and dashboard capabilities are available? 

Governance 

• How frequently will performance be reviewed? 

• Which KPIs will be monitored? 

• What is the escalation process for critical issues? 

Business Continuity 

• What happens if a critical system or resource becomes unavailable? 

• How frequently are continuity plans tested? 

The answers to these questions can reveal whether a potential provider is simply offering operational capacity—or providing genuine PV partnership. 

Key Takeaways 

• A PV partner should be more than an ICSR processing provider; it should act as an extension of the organization’s pharmacovigilance function. 

• Strong local and global regulatory expertise is essential for organizations operating across multiple markets. 

• Responsibilities, timelines, escalation pathways, and safety data exchange requirements should be clearly defined. 

• Scientific expertise is critical for signal detection, medical assessment, benefit–risk evaluation, and regulatory decision-making. 

• Quality management should include proactive compliance monitoring, CAPA, audits, training, and continuous improvement. 

• Transparency and timely escalation are essential for effective safety and compliance management. 

• Technology should support efficiency, data integrity, reporting, and oversight while maintaining appropriate human judgment. 

• Vendor and subcontractor activities require effective oversight throughout the PV supply chain. 

• Business continuity and scalability should be integral components of the partnership. 

• Regular governance and meaningful KPIs help transform outsourced PV activities into a controlled and strategically managed PV system. 

• Ultimately, the right PV partner should share the organization’s most important objective: protecting patients while maintaining a compliant and effective pharmacovigilance system.